| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H14F2N4S |
| Molecular Weight | 320.36 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]1(CCSC(N)=N1)C2=CC(=C(F)C=C2F)C3=CN=CN=C3
InChI
InChIKey=MJQMRGWYPNIERM-HNNXBMFYSA-N
InChI=1S/C15H14F2N4S/c1-15(2-3-22-14(18)21-15)11-4-10(12(16)5-13(11)17)9-6-19-8-20-7-9/h4-8H,2-3H2,1H3,(H2,18,21)/t15-/m0/s1
| Molecular Formula | C15H14F2N4S |
| Molecular Weight | 320.36 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CNS Activity
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
Sourcing
PubMed
Sample Use Guides
IN phase I studies LY2811376 was administered to healthy volunteers as oral capsules in a doses ranging from 5mg up to 500 mg once a day or twice a day for 1 day in up to 3 periods.
Route of Administration:
Oral
